Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis

BACKGROUND: Atezolizumab plus bevacizumab was approved in 2020 as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC. METHODS: Web of Science, PubMed and Embase...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xiaoqiang, Zhao, Rui, Ma, Huaxing, Zuo, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327339/
https://www.ncbi.nlm.nih.gov/pubmed/37415136
http://dx.doi.org/10.1186/s12885-023-11112-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327339/
https://www.ncbi.nlm.nih.gov/pubmed/37415136
http://dx.doi.org/10.1186/s12885-023-11112-w

Ejemplares similares